Category Archives: Neurotechnology

The Cerbat Gem

Favorable Press Coverage Very Likely to Affect Stryker Corporation (SYK) Stock Price Sports Perspectives The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. Stryker Corporation (SYK)Zacks.com all 112 news articles »

Continue reading here:

Favorable Press Coverage Very Likely to Affect Stryker Corporation (SYK) Stock Price - Sports Perspectives

Posted on June 12, 2017

Neurotechnology has announced a new version of its MegaMatcher Accelerator biometric software platform that enables faster matching than ever.

Its called MegaMatcher Accelerator Extreme, and Neurotechnology says that on a single server it can match 700 million irises per second, 1.2 billion faces per second, and 1.2 billion fingerprints per second. It can also manage 200 million iris templates, 40 million faces, and 160 million fingerprint templates on one server.

In a statement announcing the new platform, Neurotechnology called it the fastest biometric engine in the world, with the companys Director Irmantas Naujikas asserting that it will allow our customersto implement large and complex solutions in a simpler way, utilizing considerably fewer servers than before and simplifying system deployment and maintenance.

MegaMatcher Accelerator Extreme arrives soon after Neurotechnology announced an upgraded version of its SentiVeillance facial recognition SDK, which can now scan up to ten different surveillance feeds on a single computer.

June 12, 2017 by Alex Perala

Originally posted here:

Neurotechnology Announces MegaMatcher Accelerator Extreme - findBIOMETRICS

Stock Observer

Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK) Sports Perspectives The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. Stryker Corporation (SYK)Zacks.com all 66 news articles »

Follow this link:

Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK) - Sports Perspectives

June 7, 2017 - By Hazel Jackson

Stryker Corporation (NYSE:SYK) had a decrease of 3.59% in short interest. SYKs SI was 4.88M shares in June as released by FINRA. Its down 3.59% from 5.06M shares previously. With 925,900 avg volume, 5 days are for Stryker Corporation (NYSE:SYK)s short sellers to cover SYKs short positions. The SI to Stryker Corporations float is 1.49%. It closed at $144.05 lastly. It is down 24.95% since June 7, 2016 and is uptrending. It has outperformed by 8.25% the S&P500.

Welch Capital Partners Llc increased Eqt Corp (EQT) stake by 67.55% reported in 2016Q4 SEC filing. Welch Capital Partners Llc acquired 55,210 shares as Eqt Corp (EQT)s stock declined 9.10%. The Welch Capital Partners Llc holds 136,943 shares with $8.96M value, up from 81,733 last quarter. Eqt Corp now has $9.39B valuation. It closed at $53.97 lastly. It is down 18.61% since June 7, 2016 and is downtrending. It has underperformed by 35.31% the S&P500.

Stryker Corporation is a medical technology company. The company has market cap of $53.78 billion. The Firm offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. It has a 32.32 P/E ratio. The Companys divisions include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.

Among 19 analysts covering Stryker Corporation (NYSE:SYK), 12 have Buy rating, 3 Sell and 4 Hold. Therefore 63% are positive. Stryker Corporation had 34 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Stryker Corporation (NYSE:SYK) has Market Perform rating given on Tuesday, November 1 by BMO Capital Markets. The stock of Stryker Corporation (NYSE:SYK) has Buy rating given on Thursday, December 15 by UBS. Argus Research maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, April 27. Argus Research has Buy rating and $130 target. BMO Capital Markets downgraded the stock to Underperform rating in Monday, December 14 report. As per Friday, March 3, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, April 26. RBC Capital Markets has Outperform rating and $140 target. Needham downgraded the stock to Underperform rating in Friday, January 6 report. Barclays Capital initiated the shares of SYK in report on Monday, April 11 with Underweight rating. The rating was maintained by Canaccord Genuity on Wednesday, January 25 with Buy. The company was upgraded on Wednesday, April 27 by Sterne Agee CRT.

Investors sentiment increased to 0.86 in 2016 Q4. Its up 0.07, from 0.79 in 2016Q3. It increased, as 50 investors sold Stryker Corporation shares while 331 reduced holdings. 72 funds opened positions while 257 raised stakes. 277.34 million shares or 0.00% more from 277.33 million shares in 2016Q3 were reported. Savings Bank Of Montreal Can holds 0.02% or 192,296 shares in its portfolio. Rand Wealth Ltd Com reported 13,720 shares. Polar Llp holds 180,000 shares or 0.34% of its portfolio. Hall Laurie J Trustee owns 34,992 shares. 1,745 are held by Dorsey Whitney Trust Ltd. Caz Investments Limited Partnership has 1.87% invested in Stryker Corporation (NYSE:SYK) for 13,270 shares. 8,484 were reported by South Texas Money. Private State Bank Trust has 4,073 shares for 0.07% of their portfolio. Inv Services Of America Inc reported 2.26% of its portfolio in Stryker Corporation (NYSE:SYK). Next Gp Inc invested 0% in Stryker Corporation (NYSE:SYK). Saturna Cap Corporation holds 1.26% in Stryker Corporation (NYSE:SYK) or 300,000 shares. Cantab Capital Partners Limited Liability Partnership invested 0% of its portfolio in Stryker Corporation (NYSE:SYK). Family Mgmt owns 0.16% invested in Stryker Corporation (NYSE:SYK) for 2,000 shares. National Pension Ser accumulated 0.2% or 244,754 shares. Massachusetts Services Com Ma accumulated 0.67% or 11.45M shares.

Since December 9, 2016, it had 1 insider buy, and 10 sales for $13.28 million activity. FRANCESCONI LOUISE sold $454,623 worth of Stryker Corporation (NYSE:SYK) on Monday, January 30. 5,194 shares were sold by STRYKER RONDA E, worth $626,410. Lobo Kevin sold $1.30M worth of stock or 9,539 shares. Another trade for 13,322 shares valued at $1.81M was made by Scannell Timothy J on Monday, May 1. $1.40M worth of Stryker Corporation (NYSE:SYK) shares were sold by Becker Yin C. 41 shares were bought by Doliveux Roch, worth $5,048.

Welch Capital Partners Llc decreased Bright Horizons Family Solutions Inc (NYSE:BFAM) stake by 59,776 shares to 61,273 valued at $4.29M in 2016Q4. It also reduced Surgical Care Affiliates Inc. (NASDAQ:SCAI) stake by 20,830 shares and now owns 71,333 shares. Gentex Corp (NASDAQ:GNTX) was reduced too.

Since January 1, 2017, it had 2 buys, and 1 insider sale for $157,693 activity. Cary A. Bray Jr. had bought 417 shares worth $27,272 on Sunday, January 1. Another trade for 3,479 shares valued at $210,688 was sold by Hyland M Elise.

Among 20 analysts covering EQT Corporation (NYSE:EQT), 9 have Buy rating, 0 Sell and 11 Hold. Therefore 45% are positive. EQT Corporation had 43 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, June 2 by RBC Capital Markets. The firm has Hold rating by Tudor Pickering given on Thursday, October 13. On Tuesday, July 21 the stock rating was initiated by Cowen & Co with Outperform. The firm has Buy rating given on Wednesday, February 3 by GMP Securities. The stock has Buy rating by Stifel Nicolaus on Friday, August 26. The stock of EQT Corporation (NYSE:EQT) earned Hold rating by Jefferies on Tuesday, January 12. The stock of EQT Corporation (NYSE:EQT) has Hold rating given on Friday, April 7 by Jefferies. As per Friday, December 9, the company rating was downgraded by Seaport Global. As per Monday, October 24, the company rating was initiated by Credit Suisse. The stock of EQT Corporation (NYSE:EQT) has Accumulate rating given on Wednesday, January 13 by Seaport Global.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Read more from the original source:

Welch Capital Partners Increased By $3.59 Million Its Eqt (EQT) Position, Stryker (SYK) Sellers Decreased By 3.59 ... - UtahHerald.com

Comparing Accuray (ARAY) & Stryker (SYK) The Cerbat Gem The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. and more »

See the rest here:

Comparing Accuray (ARAY) & Stryker (SYK) - The Cerbat Gem

Published: 06 Jun 2017

Author: Robyn Adams

National law firm Shoosmiths has advised P D Neurotechnology (PDN) on its 1.34m (EUR) funding for the development of its ground breaking wearable medical technology.

PDN has received funding of 1,000,000 (EUR)from the founders and angel investors with a follow-on funding commitment of 340,000 (EUR)from the National Bank of Greece (NBG), 1.34m (EUR)in total. The funding will see the continued development of PDN's wearable medical technology for continuous monitoring and treating of movement disorders which is anticipated to assist in the treatment of chronic diseases like Parkinson's disease.

Shoosmiths' corporate partner Stuart Murray and solicitor Alexander Lamley advised PDN on the UK legal aspects of receiving the funding that involved a complicated structural arrangement to deal with exchange controls and NBG investment criteria.

Nikolaos Moschos, President of the board directors at PDN, commented: 'This funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit sufferers of debilitating movement disorders and illnesses such as Parkinson's disease. The team at Shoosmiths has provided effective, commercial advice with an efficient and proactive service that has ensured the timely securing of this funding.'

Stuart Murray added: 'We are extremely pleased to have assisted PDN on this significant investment into the development of their innovative medical product and wish them all the best for the future.' Shoosmiths' corporate team advises public and private companies, management teams, investors and debt providers through the business life cycle. Shoosmiths work with businesses from start-up and first round finance through to mergers and acquisitions, MBO and MBI transactions, development funding and on exits, by way of sale, listing or private equity investment.

Nationally, the corporate team is ranked in first place by deal volume in Experian's 2016 MarketIQ UK & Ireland M&A league tables. The team was recognised for its mergers and acquisitions expertise at the 2015 M&A Awards, winning the Law Firm of the Year category.

Read the original post:

Shoosmiths advises PD Neurotechnology on 1.34m (EUR) investment - Shoosmiths legal updates (press release)

Stuart Murray

Shoosmiths has advised P D Neurotechnology (PDN) on its 1.34 million funding for the development of itswearable medical technology.

PDN has received funding of 1m from the founders and angel investors with a follow-on funding commitment of 340,000 from the National Bank of Greece (NBG), 1.34m in total. The funding will see the continued development of PDNs wearable medical technology for continuous monitoring and treating of movement disorders which is anticipated to assist in the treatment of chronic diseases like Parkinsons disease.

Shoosmiths corporate partner Stuart Murrayand solicitor Alexander Lamley advised PDN on the UK legal aspects of receiving the funding that involved a complicated structural arrangement to deal with exchange controls and NBG investment criteria.

Nikolaos Moschos, president of the board directors at PDN, said: This funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit sufferers of debilitating movement disorders and illnesses such as Parkinsons disease. The team at Shoosmiths has provided effective, commercial advice with an efficient and proactive service that has ensured the timely securing of this funding.

Mr Murray added: We are extremely pleased to have assisted PDN on this significant investment into the development of their innovative medical product and wish them all the best for the future.

deals, shoosmiths June 6, 2017

View post:

Shoosmiths advises PD Neurotechnology on 1.34m investment - Scottish Legal News

Markets Daily

Stryker (SYK) Earning Somewhat Favorable Media Coverage, Report Finds Chaffey Breeze The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. Stryker Co. (SYK) Position Decreased by Cobblestone Capital ...BNB Daily (blog) (Delayed Data from NYSE)Zacks.com all 86 news articles »

Originally posted here:

Stryker (SYK) Earning Somewhat Favorable Media Coverage, Report Finds - Chaffey Breeze

Chaffey Breeze

Stryker (SYK) Receives Media Impact Score of 0.15 Chaffey Breeze The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. Electron Capital Partners Has Upped Companhia Energetica De Mina (CIG) Position; Shorts at Stryker (SYK) Raised ...Bibeypost.com (Delayed Data from NYSE)Zacks.com all 58 news articles »

Originally posted here:

Stryker (SYK) Receives Media Impact Score of 0.15 - Chaffey Breeze

Scientists can now move a mouses whiskers, ears, and a paw using just electrodes on the outside of the animals head. This new method can stimulate deep parts of the brain without surgery and if it pans out in humans it could be very helpful for people with neurological conditions like Parkinsons, depression, or epilepsy.

The brain has surface regions located near the skull and deep regions further inside, such as the motor cortex, the area of the brain that controls movement. Until now, the only real way to stimulate the regions deeper inside the brain was to cut open the skull and directly implant electrodes. (This is called deep-brain stimulation.) But surgery can be dangerous and the electrodes can cause damage inside the brain. In a study published today in the journal Cell, a team of scientists at the Massachusetts Institute of Technology showed a way to sidestep the dangerous surgery and stimulate the motor cortex from the outside.

To do this, the team took advantage of how neurons process electrical signals. Neurons only activate when they receive low-frequency electricity signals. If high-frequency signals are applied to the brain, the brain just ignores them. It cant keep up, says study co-author Ed Boyden, a cognitive scientist at MIT.

But something interesting happens when you send two high-frequency signals that are just a little bit different, like 3000 hertz and 3001 hertz. Most parts of the brain ignore the signals. But when the two frequencies meet at the target site in this case, the motor cortex and interfere with each other, the neurons pay attention. They interpret the difference in frequency as if it were a low-frequency wave. This technique, called temporal interference, makes it possible to stimulate just one part of the brain and not all the other parts on the way there.

Thats exactly what the team did. After calculating the right frequencies to target the motor cortex, they sent the two frequencies to the mouse brains. In this way, they made the animal wiggle its ears, whiskers, and a paw.

The technique could potentially help humans with certain conditions. In a disease like Parkinsons, for instance, the motor cortex sends and receives abnormal electrical signals. This causes people to have tremors and their muscles to weaken. With traditional deep-brain stimulation, the electrode implanted in the brain blocks these abnormal signals, which helps control the tremors for up to five years. Ideally, says Boyden, with the new technique one day you could stimulate a human brain from the outside for a brief amount of time, and have the effects last for the rest of the day or the rest of the week.

This technique has potential to be an extremely useful tool to both probe and potentially change the functioning of brain regions and brain circuits that are very important to a lot of human illnesses, says Ben Greenberg, associate director of Providence VA Hospitals Center for Neurorestoration and Neurotechnology, who was not involved in the study. But he notes that its simply too soon to say how this stacks against deep-brain stimulation, which has been researched since the 1980s.

There are many questions that need to be answered. We dont know yet how precise this new method can be; for now, we just know its nowhere near as precise as implantable devices. Safety is another concern: early tests showed that this type of stimulation didnt harm the animals, but more research needs to be done, according to Boyden.

And, of course, the big question is how useful this could be in humans. For one, the human skull is thicker than a mouses, which will change the types of frequencies needed. Plus, different people might respond to frequencies differently, says Greenberg. Even in the mice, there were differences in how responsive their cells were.

Boydens team is already doing more safety experiments with animals, and early studies with human volunteers. We want to be as careful as possible, of course, Boyden says, but the good news is that since were building from decades of research on electric fields, so its not like were starting from scratch.

The rest is here:

Scientists remotely move a mouse's whiskers with electrodes outside its brain - The Verge